The average copy number variation (CNVA) of chromosome fragments is a potential surrogate for tumor mutational burden in predicting responses to immunotherapy in non‐small‐cell lung cancer

The tumor mutational burden (TMB) is closely related to immunotherapy outcome. However, the cost of TMB detection is extremely high, which limits its use in clinical practice. A new indicator of genomic instability, the average copy number variation (CNVA), calculates the changes of 0.5‐Mb chromosomal fragments and requires extremely low sequencing depth.

[1]  S. Digumarthy,et al.  Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50% , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  David R. Riley,et al.  Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade , 2019, Clinical Cancer Research.

[3]  T. John,et al.  DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it? , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  J. Ahn,et al.  DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  S. Fröhling,et al.  Optimizing panel-based tumor mutational burden (TMB) measurement. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  S. Lippman,et al.  Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy , 2019, Cancer Immunology Research.

[7]  A. Scarpa,et al.  ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Duhee Bang,et al.  Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin , 2019, Clinical Cancer Research.

[9]  J. Ross,et al.  Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Nishino,et al.  Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer , 2019, Journal of Immunotherapy for Cancer.

[11]  S. Qiu,et al.  HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1 , 2019, Journal of Immunotherapy for Cancer.

[12]  Donna Niedzwiecki,et al.  Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Matthew D. Hellmann,et al.  First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[15]  A. Tsao.  First-Line Nivolumab plus Ipilimumab for Advanced Non–Small-Cell Lung Cancer , 2018 .

[16]  Ahmet Zehir,et al.  Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Scarpi,et al.  DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy , 2017, OncoTargets and therapy.

[18]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[19]  A. Thompson,et al.  Multiparameter DNA content analysis identifies distinct groups in primary breast cancer , 2013, British Journal of Cancer.

[20]  M. Bento,et al.  DNA content in malignant salivary gland tumours. , 2009, Oral diseases.

[21]  C. Cantor,et al.  Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma , 2008, Proceedings of the National Academy of Sciences.

[22]  J. Soares,et al.  Frequent 7q gains in flow cytometric multiploid/hypertetraploid breast carcinomas: a study of chromosome imbalances by comparative genomic hybridisation , 2006, Journal of Clinical Pathology.

[23]  T. Sugai,et al.  Analysis of Genetic Alterations Associated with DNA Diploidy, Aneuploidy and Multiploidy in Gastric Cancers , 2005, Oncology.

[24]  B. Plancoulaine,et al.  Flow cytometry in primary breast carcinomas: Prognostic impact of S‐phase fraction according to different analysis patterns , 2004, Cytometry. Part B, Clinical cytometry.

[25]  T. Delozier,et al.  Flow cytometry in primary breast carcinomas: Prognostic impact of multiploidy and hypoploidy , 2003, Cytometry. Part B, Clinical cytometry.

[26]  Kazuyuki Suzuki,et al.  Analysis of genetic alterations, classified according to their DNA ploidy pattern, in the progression of colorectal adenomas and early colorectal carcinomas , 2003, The Journal of pathology.

[27]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.